Dr. Fountzilas is a board certified medical oncologist in the gastrointestinal medical oncology department at Roswell Park Cancer Institute with a focus in pancreatic cancer. His research interests include oncolytic virotherapy, biomarker discovery, and immunotherapy for gastrointestinal cancers. His interest was sparked in gastrointestinal and clinical research during his fellowship training at the University of Texas Health Science Center at San Antonio where he designed a clinical trial involving combination immunotherapy and oncolytic viral therapy in relapsed adenocarcinoma of the pancreas. He gained further experience in clinical trial design through his participation in the American Association for Cancer Research/American Society of Clinical Oncology 2015 Methods in Clinical Cancer Research Workshop and Cancer Research Training Program from Cancer Prevention and Research Institute of Texas.
- Fountzilas C, Patel S, Mahalingam D. Oncolytic Virotherapy, updates and future directions. Oncotarget. In press.
- Mahalingam D, Fountzilas C, Moseley J, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Coffey M, Thompson B, John Sarantopoulos J. A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. Cancer Chemother Pharmacol. 2017 Apr; 79(4): 697-703. doi: 10.1007/s00280-017-3260-6.
- Fountzilas C, Chang K, Hernandez B, Michalek J, Crownover R, Floyd J, Mahalingam D. Clinical characteristics and treatment outcomes of patients with colorectal cancer who develop brain metastasis: A single institution experience. J Gastrointest Oncol. 2017 Feb;8(1): 55-63. doi: 10.21037/jgo.2016.12.11.
- Fountzilas C, Stuart S, Hernandez B, Bowhay-Carnes E, Michalek J, Sarantopoulos J, Karnad A, Patel S, Weitman S, Mahalingam D. Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials? Invest New Drugs. 2017 Jan 19. doi: 10.1007/s10637-017-0425-4. Christos